← Back to Search

Virus Therapy

JNJ-81201887 for Age-Related Macular Degeneration

Phase 2
Recruiting
Research Sponsored by Janssen Research & Development, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003)
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up upto 5 years

Summary

This trial aims to check the safety and how well people can tolerate JNJ-81201887 after getting a shot in the eye, based on previous studies. "This trial aims to assess the long

Who is the study for?
This trial is for individuals with Geographic Atrophy (GA) secondary to Age-related Macular Degeneration (AMD). Participants must have previously received JNJ-81201887 in parent studies and meet other study-specific requirements.
What is being tested?
The focus of this study is on the long-term safety and effects of JNJ-81201887, which is given as an injection into the eye. The trial includes a comparison group receiving a sham procedure to evaluate differences over time.
What are the potential side effects?
Potential side effects may include discomfort at the injection site, changes in vision, eye inflammation or infection, and possible systemic effects due to medication absorption.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I was part of a study and received treatment with JNJ-81201887 or a placebo.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~upto 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and upto 5 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants with Abnormal Findings in Clinical Laboratory Assessments
Number of Participants with Abnormal Findings in Retinal imaging and Eye Examinations
Number of Participants with Ocular and Systemic Treatment-emergent Adverse Events (TEAEs)

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm B: JNJ-81201887 High doseExperimental Treatment1 Intervention
Study participants who were enrolled and received treatment with high dose JNJ-81201887 in parent clinical studies (81201887MDG2001 \[NCT05811351\]; 81201887MDG1003) will enter this LTE study. No study intervention will be administered as part of this study.
Group II: Arm A: JNJ-81201887 Low DoseExperimental Treatment1 Intervention
Study participants who were enrolled and received treatment with low dose JNJ-81201887 in parent clinical studies (81201887MDG2001 \[NCT05811351\]; 81201887MDG1003) will enter this long-term extension (LTE) study. No study intervention will be administered as part of this study.
Group III: Arm C: Sham ProcedurePlacebo Group1 Intervention
Participants randomized to the sham arm in parent study 81201887MDG2001 (NCT05811351) may have the option to receive JNJ-81201887 open-label treatment under a separate protocol after unmasking of that study; and will enter this LTE study. No intervention will be administered as part of this study.

Find a Location

Who is running the clinical trial?

Janssen Research & Development, LLCLead Sponsor
992 Previous Clinical Trials
6,386,582 Total Patients Enrolled
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
758 Previous Clinical Trials
3,962,382 Total Patients Enrolled
~207 spots leftby Aug 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top